|
KMID : 1030220220230010001
|
|
Journal of Korean Diabetes
2022 Volume.23 No. 1 p.1 ~ p.6
|
|
|
Glucose-Lowering Agents and COVID-19
|
|
Khang Ah-Reum
|
|
|
Abstract
|
|
|
|
Coronavirus disease 2019 (COVID-19) is continuing to spread around the world despite the introduction of vaccines. Individuals with diabetes have been reported to have more severe clinical outcomes of COVID-19 infection. As there is potential that glucose-lowering agents can influence the clinical outcomes in diabetic patients with COVID-19, a number of studies are ongoing to explore the differences in clinical outcomes related to glucose-lowering agents. In this article, I summarize the published research on the relationship between glucose-lowering agents and clinical outcomes of diabetic patients with COVID-19 and suggest clinical consideration for usage of glucose-lowering agents.
|
|
|
KEYWORD
|
|
|
COVID-19, Diabetes mellitus, Hypoglycemic agents, SARS-CoV-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|